



EPKINLY® CONTINUES TO ELICIT DEEP AND DURABLE RESPONSE IN 3L/3L+ DLBCL*1

At 25.1-mo median follow-up of the EPCORE NHL-1 trial¹:



ORR

61.9%

(95% CI, 53.3–70.0)¹



Estimated complete responders remained in CR at 24mo

61.8%

(95% CI, 44.9–74.9)¹



DOCR[†]

Estimated OS rate in complete responders at 24mo

77.4%

(95% CI, 63.6–86.5)¹



OS[†]

Epkinly®-treated DLBCL patients achieved mOS of 19.4 mo (95% CI, 11.7–27.7)¹

Please scan the QR code for the API



¹The pivotal EPCORE NHL-1 trial investigated long-term efficacy and safety results in patients with LBCL (N=157) for up to 2 years, with a median follow-up of 25.1 months.¹ Results for DLBCL (n=139) and DLBCL or HGBCL (n=148) subpopulations were also reported.¹

[†]On the basis of the Kaplan-Meier estimate.¹

Abbreviations: 3L, third line; 3L+, third line or later; CI, confidence interval; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DOCR, duration of complete response; HGBCL, high-grade B-cell lymphoma; LBCL, large B-cell lymphoma; mo, months; mOS, median overall survival; ORR, objective response rate; OS, overall survival
Reference: 1. Thieblemont C, et al. *Leukemia*. 2024;38(12):2653–62.

All adverse events should be reported to PVChina@abbvie.com.
For healthcare professionals only
HK-EDLBCL-25000117/JAN/2025



AbbVie Limited
Unit 2405-08, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong
Tel: (852) 3467 8888 Fax: (852) 2219 7397

